N. Pujol-Moix, B. Jiménez, E. Muñiz-Díaz, M. Roca, J. Souto
{"title":"Familial Immune Thrombocytopenia. Report of 16 Cases and Literature Review","authors":"N. Pujol-Moix, B. Jiménez, E. Muñiz-Díaz, M. Roca, J. Souto","doi":"10.29245/2572-9411/2018/4.1167","DOIUrl":"https://doi.org/10.29245/2572-9411/2018/4.1167","url":null,"abstract":"Familial Immune Thrombocytopenia. Report of 16 Cases and Literature Review Núria Pujol-Moix1,2*, Blanca Jimenez2, Eduardo Muñiz-Diaz3, Manel Roca4, Joan Carles Souto2,5 1Medicine Department, Unitat Docent Sant Pau, Universitat Autònoma de Barcelona, Spain 2Institute of Biomedical Research (IIB-Sant Pau), Barcelona, Spain 3Division of Immunohematology, Banc de Sang i Teixits de Catalunya, Barcelona, Spain 4Nuclear Medicine Department, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Spain 5Unitat d’Hemostàsia i Trombosi, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain","PeriodicalId":91764,"journal":{"name":"Journal of rare diseases research & treatment","volume":"123 6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88520047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Frequency Analysis for The Effect of Pico Tesla-Transcranial Magnetic Stimulation in Epilepsy Patients Using Magnetoencephalography","authors":"P. Anninos","doi":"10.29245/2572-9411/2018/4.1164","DOIUrl":"https://doi.org/10.29245/2572-9411/2018/4.1164","url":null,"abstract":"The purpose of this research is to identify any change in the frequencies of 2-7Hz in the brain state of epilepsy patients after pico-Tesla transcranial magnetic stimulation (pT-TMS). It is a noninvasive technique for treating neurological disorders. We used magneto encephalographic (MEG) recordings of 10 epilepsy patients with a whole-head 122 channel MEG system in a magnetically shielded room of low magnetic noise. The subjects were 5 male and 5 female epilepsy volunteers between 18-42 years of age. Afterwards, external pT-TMS was applied to the above patients. A software program was developed in our lab in order to detect the primary dominant frequency of the power spectra of the MEG obtained from every patient and channel before and after the application of pT-TMS. We found that 7 out of 10 patients (70%) had increased their 2-7Hz frequencies after the application of pT-TMS. We concluded that frequency analysis is a promising means for the assessment of epilepsy disorders.","PeriodicalId":91764,"journal":{"name":"Journal of rare diseases research & treatment","volume":"119 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73377952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Chemoradiotherapy Versus Chemotherapy for Localized Gastric Cancer: A Mini Review","authors":"D. Girardi","doi":"10.29245/2572-9411/2018/3.1159","DOIUrl":"https://doi.org/10.29245/2572-9411/2018/3.1159","url":null,"abstract":"Curative treatment for localized gastric cancer involves a multidisciplinary approach that includes surgery and chemotherapy with or without radiotherapy. In the past decades several studies have shown survival benefit of postoperative and perioperative treatments in comparison with surgery alone. Only a few trials have compared directly chemotherapy with chemoradiotherapy without a clear benefit favoring one strategy over another. In the absence of a standard approach, the choice of the best treatment is individualized and varies by geographic region and the preference of the institution where the patient is being treated. This review summarizes what is new in the treatment of localized gastric cancer and seeks to deeply analyze chemotherapy and chemoradiotherapy strategies.","PeriodicalId":91764,"journal":{"name":"Journal of rare diseases research & treatment","volume":"62 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75350393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Rodríguez-González, Alvaro Antonio Perez-Reviriego, Ana Castellano-Martínez, Helena Maria Cascales-Poyatos
{"title":"Cardiac Complications in Patients with Propionic Acidemia","authors":"M. Rodríguez-González, Alvaro Antonio Perez-Reviriego, Ana Castellano-Martínez, Helena Maria Cascales-Poyatos","doi":"10.29245/2572-9411/2018/3.1162","DOIUrl":"https://doi.org/10.29245/2572-9411/2018/3.1162","url":null,"abstract":"Propionic acidemia, is an autosomal recessive disorder due to the deficiency of the enzyme propionyl‐coenzyme A carboxylase, which is a critical component for the metabolism of certain amino acids and lipids. The clinical complications are varied and may present at any time in the patient’s life, mainly the neurological symptoms. Outside the central nerve system, haematological abnormalities including anaemia, neutropenia, thrombocytopenia or pancytopenia, immune defects, osteoporosis and pancreatitis are other rare complications reported. Of note, cardiac diseases have been recognized as increasing and life‐threatening manifestations, including cardiomyopathy and electrophysiological changes such as prolongation of the QT interval.","PeriodicalId":91764,"journal":{"name":"Journal of rare diseases research & treatment","volume":"55 7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90054507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Potential Pithfalls in Using HPLC and its Interpretation in Diagnosing HbS","authors":"S. Nair","doi":"10.29245/2572-9411/2018/3.1161","DOIUrl":"https://doi.org/10.29245/2572-9411/2018/3.1161","url":null,"abstract":"Hemoglobinopathies are the most common group of autosomal recessive monogenic disorders worldwide. They include both thalassemias and structural hemoglobin variants. More than 1,100 hemoglobin variants have been detected so far out which majority of them are new variants while some others are very commonly found in some populations 1, 2,3. Sickle hemoglobin (Hb S) is a very common structural variant found worldwide. Sickle cell disorder is a group of hereditary blood disorders caused due to a mutation in the β globin gene resulting in the production of abnormal hemoglobin called sickle hemoglobin (Hb S). Hb S is so called because the abnormal hemoglobin causes the red blood cells to become rigid and sickle shaped which blocks blood flow and breaks down easily4. Severity in sickle cell disorders varies and the symptoms range from anemia to vaso-occlusive crises which over a period of time affect multiple organs with chronic deterioration over the time5. When the sickle mutation is inherited with any other globin gene mutation it is called variant sickle cell syndromes and the clinical severity may differ when compared to homozygous sickle mutation6. Early detection of sickle cell disease (SCD) helps in the prophylactic therapy7 and proper management of the disease5. This is the reason why new born or neonatal screening programs for sickle cell disorders have been initiated in many countries where the prevalence of sickle cell anemia is very high8,9 .Therefore it becomes all the more important that extreme precaution has to be taken while diagnosing sickle cell disease as it provides a direction for life long treatment and prophylaxis of the patient along with counselling of the parents for prenatal diagnosis or pre implantation genetic diagnosis in future pregnancies3,10. Bone marrow transplant with HLA identical donors and use of hydroxyurea may be beneficial to reduce frequency of crises and reduce tissue damage11.","PeriodicalId":91764,"journal":{"name":"Journal of rare diseases research & treatment","volume":"216 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72839619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Geographic Diversity in Atypical Hemolytic Uremic Syndrome (aHUS): The Genetic Background of aHUS Cohort in Japan","authors":"Yoichiro Ikeda","doi":"10.29245/2572-9411/2018/3.1156","DOIUrl":"https://doi.org/10.29245/2572-9411/2018/3.1156","url":null,"abstract":"Atypical hemolytic uremic syndrome (aHUS) is a rare disease caused by the dysfunction of the alternative pathway of the complement system, which leads to the spontaneous activation of the complement system in the circulating plasma or cell surface. Recently our group published the cohort analysis of aHUS in Japan (n=118). Through the study, we revealed the followings; 1) the genetic background of aHUS in Japan was different from that in Western countries, 2) the most frequent genetic mutation detected in this study was I1157T in C3 (n=24), which was associated with superior renal outcome in spite of frequent replases, 3) Anti-CFH antibody positive aHUS had an excellent renal outcome, 4) 44% cases presented nephrotic syndrome, 5) only 12 % developed end stage renal disease (ESRD) and 6) there were 13 cases that discontinued eculizumab treatment and were followed up. These findings might help establishing the robust evidence for the optimal treatment of aHUS.","PeriodicalId":91764,"journal":{"name":"Journal of rare diseases research & treatment","volume":"75 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86412302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Natalie M Bath, Daniel H Williams, Hans W Sollinger, Robert R Redfield
{"title":"Commentary: Loin Pain Hematuria Syndrome.","authors":"Natalie M Bath, Daniel H Williams, Hans W Sollinger, Robert R Redfield","doi":"10.29245/2572-9411/2018/4.1169","DOIUrl":"https://doi.org/10.29245/2572-9411/2018/4.1169","url":null,"abstract":"<p><p>Loin Pain Hematuria Syndrome (LPHS) remains a rare disease but has a significant impact on those affected by it. Patients diagnosed with LPHS experience severe, constant or intermittent flank pain that radiates to the groin and may be exacerbated even by a gentle touch. These patients often require significant narcotic regimens for pain control and are unable to maintain a functional lifestyle. Previously, diagnosis has been made based on clinical presentation. One treatment for this syndrome is renal autotransplant; however, success rates are varied. Therefore, patient selection for this procedure is important. We have developed the UW-LPHS test as a diagnostic maneuver in order to determine which patients with LPHS would benefit from renal autotransplant. To perform this diagnostic test, bupivacaine is instilled into the ureter on the affected side and left to dwell. Patients who experience pain relief following this test are deemed to benefit from renal autotransplant. Here we describe this novel diagnostic test and initial success rates following renal autotransplant.</p>","PeriodicalId":91764,"journal":{"name":"Journal of rare diseases research & treatment","volume":"3 4","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457464/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37154306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Commentary: Individuals affected by Eosinophilic Gastrointestinal Disorders Have Complex Unmet Needs and Experience Barriers to Care.","authors":"Girish Hiremath, Evan S Dellon","doi":"10.29245/2572-9411/2018/2.1155","DOIUrl":"10.29245/2572-9411/2018/2.1155","url":null,"abstract":"","PeriodicalId":91764,"journal":{"name":"Journal of rare diseases research & treatment","volume":"3 2","pages":"34-36"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404763/pdf/nihms-997249.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37041145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Waardenburg Syndrome Expression and Penetrance","authors":"M. Shelby","doi":"10.29245/2572-9411/2017/6.1118","DOIUrl":"https://doi.org/10.29245/2572-9411/2017/6.1118","url":null,"abstract":"Through a combination of in silico research and reviews of previous work, mechanisms by which nonsense-mediated mRNA decay (NMD) affects the inheritance and expressivity of Waardenburg syndrome is realized. While expressivity and inheritance both relate to biochemical processes underlying a gene’s function, this research explores how alternative splicing and premature termination codons (PTC’s) within mRNAs mutated in the disease are either translated into deleterious proteins or decayed to minimize expression of altered proteins. Elucidation of splice variants coupled with NMD perpetuating the various symptoms and inheritance patterns of this disease represent novel findings. By investigating nonsense mutations that lie within and outside the NMD boundary of these transcripts we can evaluate the effects of protein truncation versus minimized protein expression on the variable expressivity found between Type I and Type III Waardenburg syndrome, PAX3, while comparatively evaluating EDN3 and SOX10’s role in inheritance of Type IV subtypes of the disease. This review will demonstrate how alternative splicing perpetuates or limits NMD activity by way of PTC positioning, thereby affecting the presentation of Waardenburg syndrome.","PeriodicalId":91764,"journal":{"name":"Journal of rare diseases research & treatment","volume":"43 1","pages":"31 - 40"},"PeriodicalIF":0.0,"publicationDate":"2017-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81113268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Sarathy, A. Nunes, Tatiana M Fontelonga, Tracy Y. Ogata, D. Burkin
{"title":"Commentary: SU9516 increases α7β1 Integrin and Ameliorates Disease Progression in the mdx Mouse Model of Duchenne Muscular Dystrophy","authors":"A. Sarathy, A. Nunes, Tatiana M Fontelonga, Tracy Y. Ogata, D. Burkin","doi":"10.29245/2572-9411/2017/5.1126","DOIUrl":"https://doi.org/10.29245/2572-9411/2017/5.1126","url":null,"abstract":"Duchenne muscular dystrophy (DMD) is a debilitating X-linked neuromuscular disease with an incidence of 1 in every 5000 boys1. It is caused by mutations in the DMD gene coding for dystrophin, a critical structural protein in muscle. Out-of-frame mutations in the DMD gene, result in the complete loss of dystrophin in muscle fibers2,3 and this leads to a severe disease characterized by progressive muscle deterioration. The functional role of dystrophin is to stabilize the dystrophin glycoprotein complex (DGC), which is composed of sarcolemmal glycoproteins that link the extracellular matrix (ECM) to the actin cystoskeleton in muscle fibers4,5. In the absence of dystrophin, this critical link is lost, rendering the muscle fibers susceptible to damage and contraction-induced injury. Until recently, palliative interventions such as glucocorticoid and corticosteroids were the only options available for disease management in DMD patients. These were accompanied by numerous side effects including weight gain, stunted growth, cataracts and susceptibility to skeletal fractures6,7. In September 2016, the Food and Drug Administration approved a drug for the treatment of patients with amenable mutations in exon 51 of the dystrophin gene. The drug Eteplirsen, a phosphorodiamidate oligonucleotide (PMO), is an exon skipping molecule8 which skips its target exon 51, thereby restoring the dystrophin translational reading frame and enabling expression of a truncated dystrophin molecule in patient muscle fibers. Eteplirsen addresses only 13% of DMD patients because it is mutation-specific9 and a therapeutic that can be universally administered to all DMD patients is still needed.","PeriodicalId":91764,"journal":{"name":"Journal of rare diseases research & treatment","volume":"19 1","pages":"1 - 4"},"PeriodicalIF":0.0,"publicationDate":"2017-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88780644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}